Alnylam Q2 revenue rises 67% on increased demand for AMVUTTRA
ALNY•Outlook
- Alnylam lowers 2026 TTR net product revenue guidance to $4.2 bln-$4.5 bln
- Company maintains 2026 Rare net product revenue guidance at $500 mln-$600 mln
- Alnylam expects 2026 net revenues from collaborations and royalties of $575 mln-$625 mln
Overview
- RNAi therapeutics maker's Q2 revenue rose 67% yr/yr but missed analyst expectations
- Adjusted EPS for Q2 beat analyst expectations
- Company lowered full-year TTR revenue guidance due to normalized second-line demand for AMVUTTRA
Result Drivers
- AMVUTTRA demand - Growth in Q2 revenue was primarily driven by increased patient demand for AMVUTTRA, especially among U.S. patients with ATTR-CM
- Normalized second-line demand - Co said initial pent-up demand for AMVUTTRA in the U.S. second-line segment has normalized, leading to revised full-year TTR revenue guidance
- International TTR growth - International TTR revenues rose, driven by increased demand in both hATTR-PN and ATTR-CM across international markets
